

Steen Dalby Kristensen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2447991/publications.pdf>

Version: 2024-02-01

91
papers

12,827
citations

147801

31
h-index

48315

88
g-index

93
all docs

93
docs citations

93
times ranked

15454
citing authors

#	ARTICLE	IF	CITATIONS
1	2013 ESC guidelines on the management of stable coronary artery disease. <i>European Heart Journal</i> , 2013, 34, 2949-3003.	2.2	3,915
2	2012 focused update of the ESC Guidelines for the management of atrial fibrillation. <i>European Heart Journal</i> , 2012, 33, 2719-2747.	2.2	3,144
3	Universal Definition of Myocardial Infarction. <i>Circulation</i> , 2007, 116, 2634-2653.	1.6	2,755
4	New Oral Anticoagulants in Atrial Fibrillation and Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2012, 59, 1413-1425.	2.8	257
5	Antiplatelet agents for the treatment and prevention of atherothrombosis. <i>European Heart Journal</i> , 2011, 32, 2922-2932.	2.2	203
6	Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial. <i>Lancet, The</i> , 2010, 375, 1090-1099.	13.7	198
7	Immature platelets in patients with acute coronary syndromes. <i>Thrombosis and Haemostasis</i> , 2009, 101, 151-153.	3.4	171
8	Evaluation of Coronary Artery Stenosis by Quantitative Flow Ratio During Invasive Coronary Angiography. <i>Circulation: Cardiovascular Imaging</i> , 2018, 11, e007107.	2.6	157
9	A comparison of platelet function tests and thromboxane metabolites to evaluate aspirin response in healthy individuals and patients with coronary artery disease. <i>Thrombosis and Haemostasis</i> , 2010, 103, 1245-1253.	3.4	125
10	Zotarolimus-eluting durable-polymer-coated stent versus a biolimus-eluting biodegradable-polymer-coated stent in unselected patients undergoing percutaneous coronary intervention (SORT OUT VI): a randomised non-inferiority trial. <i>Lancet, The</i> , 2015, 385, 1527-1535.	13.7	107
11	Randomized Comparison of a Biodegradable Polymer Ultrathin Strut Sirolimus-Eluting Stent With a Biodegradable Polymer Biolimus-Eluting Stent in Patients Treated With Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, .	3.9	104
12	Platelet aggregation is dependent on platelet count in patients with coronary artery disease. <i>Thrombosis Research</i> , 2012, 129, 56-61.	1.7	100
13	Differential clinical outcomes after 1 year versus 5 years in a randomised comparison of zotarolimus-eluting and sirolimus-eluting coronary stents (the SORT OUT III study): a multicentre, open-label, randomised superiority trial. <i>Lancet, The</i> , 2014, 383, 2047-2056.	13.7	96
14	Risk Associated With Surgery Within 12 Months After Coronary Drug-Eluting Stent Implantation. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2622-2632.	2.8	89
15	Nonculprit Stenosis Evaluation Using Instantaneous Wave-Free Ratio in Patients With ST-Segment Elevation Myocardial Infarction. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 2528-2535.	2.9	55
16	Contemporary use of glycoprotein IIb/IIIa inhibitors. <i>Thrombosis and Haemostasis</i> , 2012, 107, 215-224.	3.4	54
17	Impact of Coronavirus Disease 2019 (COVID-19) Outbreak on Acute Admissions at the Emergency and Cardiology Departments Across Europe. <i>American Journal of Medicine</i> , 2021, 134, 482-489.	1.5	53
18	Magnesium Inhibits Platelet Activity - an Infusion Study in Healthy Volunteers. <i>Thrombosis and Haemostasis</i> , 1996, 75, 939-944.	3.4	52

#	ARTICLE	IF	CITATIONS
19	Platelet Turnover in Stable Coronary Artery Disease – Influence of Thrombopoietin and Low-Grade Inflammation. PLoS ONE, 2014, 9, e85566.	2.5	50
20	Randomized Comparison of the Polymer-Free Biolimus-Coated BioFreedom Stent With the Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Orsiro Stent in an All-Comers Population Treated With Percutaneous Coronary Intervention. Circulation, 2020, 141, 2052-2063.	1.6	48
21	Computed tomography derived fractional flow reserve testing in stable patients with typical angina pectoris: influence on downstream rate of invasive coronary angiography. European Heart Journal Cardiovascular Imaging, 2018, 19, 405-414.	1.2	45
22	Quantitative flow ratio for immediate assessment of nonculprit lesions in patients with ST-segment elevation myocardial infarction – An iSTEMI substudy. Catheterization and Cardiovascular Interventions, 2019, 94, 686-692.	1.7	45
23	Implementation of primary angioplasty in Europe: Stent for Life initiative progress report. EuroIntervention, 2012, 8, 35-42.	3.2	45
24	Rapid evaluation of platelet function using the Multiplate® Analyzer. Platelets, 2014, 25, 628-633.	2.3	43
25	Magnesium Inhibits Platelet Activity - An In Vitro Study. Thrombosis and Haemostasis, 1996, 76, 088-093.	3.4	39
26	Genetic Determinants of On-Aspirin Platelet Reactivity: Focus on the Influence of PEAR1. PLoS ONE, 2014, 9, e111816.	2.5	39
27	Pharmacogenetics of the Antiplatelet Effect of Aspirin. Current Pharmaceutical Design, 2012, 18, 5294-5308.	1.9	37
28	Determinants of Reduced Antiplatelet Effect of Aspirin in Patients with Stable Coronary Artery Disease. PLoS ONE, 2015, 10, e0126767.	2.5	37
29	Antiplatelet and anticoagulation agents in acute coronary syndromes: What is the current status and what does the future hold?. American Heart Journal, 2014, 168, 611-621.	2.7	34
30	Platelet characteristics in patients with essential thrombocytosis. Cytometry Part B - Clinical Cytometry, 2018, 94, 918-927.	1.5	33
31	Platelet Number and Volume during Myocardial Infarction in Relation to Infarct Size. Acta Medica Scandinavica, 1986, 220, 401-405.	0.0	32
32	Fibrin Clot Structure and Platelet Aggregation in Patients with Aspirin Treatment Failure. PLoS ONE, 2013, 8, e71150.	2.5	32
33	Antiplatelet therapy in acute coronary syndromes. Expert Opinion on Pharmacotherapy, 2015, 16, 2133-2147.	1.8	30
34	The influence of low-grade inflammation on platelets in patients with stable coronary artery disease. Thrombosis and Haemostasis, 2015, 114, 519-529.	3.4	28
35	Increased platelet aggregation and turnover in the acute phase of ST-elevation myocardial infarction. Platelets, 2013, 24, 528-537.	2.3	27
36	Reduced antiplatelet effect of aspirin is associated with low-grade inflammation in patients with coronary artery disease. Thrombosis and Haemostasis, 2013, 109, 920-929.	3.4	27

#	ARTICLE	IF	CITATIONS
37	Everolimus-Eluting Versus Biolimus-Eluting Stents With Biodegradable Polymers in Unselected Patients Undergoing Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 624-633.	2.9	27
38	Impact of Health Care System Delay in Patients With ST-Elevation Myocardial Infarction on Return to Labor Market and Work Retirement. <i>American Journal of Cardiology</i> , 2014, 114, 1810-1816.	1.6	25
39	Platelets and Antiplatelet Therapy in Patients with Coronary Artery Disease and Diabetes. <i>Seminars in Thrombosis and Hemostasis</i> , 2016, 42, 234-241.	2.7	25
40	Coronary artery disease-associated genetic variants and biomarkers of inflammation. <i>PLoS ONE</i> , 2017, 12, e0180365.	2.5	25
41	Increased platelet aggregation and serum thromboxane levels in aspirin-treated patients with prior myocardial infarction. <i>Thrombosis and Haemostasis</i> , 2012, 108, 140-147.	3.4	17
42	Detection of biomarkers using a novel proximity extension assay in patients with ST-elevation myocardial infarction. <i>Thrombosis Research</i> , 2018, 172, 21-28.	1.7	17
43	Calprotectin and Platelet Aggregation in Patients with Stable Coronary Artery Disease. <i>PLoS ONE</i> , 2015, 10, e0125992.	2.5	17
44	How can we optimize the processes of care for acute coronary syndromes to improve outcomes?. <i>American Heart Journal</i> , 2014, 168, 622-631.e2.	2.7	16
45	A genetic risk score predicts cardiovascular events in patients with stable coronary artery disease. <i>International Journal of Cardiology</i> , 2017, 241, 411-416.	1.7	16
46	Fibrin clot lysis assay: Establishment of a reference interval. <i>Thrombosis Research</i> , 2018, 167, 9-11.	1.7	16
47	Immature Platelets and Risk of Cardiovascular Events among Patients with Ischemic Heart Disease: A Systematic Review. <i>Thrombosis and Haemostasis</i> , 2021, 121, 659-675.	3.4	16
48	The Influence of Haemoglobin A1c Levels on Platelet Aggregation and Platelet Turnover in Patients with Coronary Artery Disease Treated with Aspirin. <i>PLoS ONE</i> , 2015, 10, e0132629.	2.5	15
49	Reduced Antiplatelet Effect of Aspirin Does Not Predict Cardiovascular Events in Patients With Stable Coronary Artery Disease. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	14
50	Once- versus twice-daily aspirin treatment in patients with essential thrombocytosis. <i>Platelets</i> , 2019, 30, 322-328.	2.3	14
51	Effect of remote ischaemic conditioning on coagulation and fibrinolysis. <i>Thrombosis Research</i> , 2016, 141, 129-135.	1.7	13
52	Neutrophil gelatinase-associated lipocalin (NGAL) and cardiovascular events in patients with stable coronary artery disease. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2018, 78, 470-476.	1.2	13
53	MicroRNA as Biomarkers for Platelet Function and Maturity in Patients with Cardiovascular Disease. <i>Thrombosis and Haemostasis</i> , 2022, 122, 181-195.	3.4	13
54	Validation of the European Society of Cardiology and European Society of Anaesthesiology non-cardiac surgery risk score in patients treated with coronary drug-eluting stent implantation. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2019, 5, 22-27.	4.0	12

#	ARTICLE	IF	CITATIONS
55	External applicability of the COMPASS trial: the Western Denmark Heart Registry. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 192-199.	3.0	12
56	Impact of diabetes on clinical outcomes after revascularization with sirolimus-eluting and biolimus-eluting stents with biodegradable polymer from the SORT OUT VII trial. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, 567-573.	1.7	11
57	Comparison of Frequency of Ischemic Stroke in Patients With Versus Without Coronary Heart Disease and Without Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2019, 123, 153-158.	1.6	10
58	Recurrent Cardiovascular Events Despite Antiplatelet Therapy in a Patient with Polycythemia Vera and Accelerated Platelet Turnover. <i>American Journal of Case Reports</i> , 2017, 18, 945-948.	0.8	9
59	Smoking is the dominating modifiable risk factor in younger patients with STEMI. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020, 9, 70-75.	1.0	9
60	The ABO locus is associated with increased platelet aggregation in patients with stable coronary artery disease. <i>International Journal of Cardiology</i> , 2019, 286, 152-158.	1.7	8
61	Dual antithrombotic treatment in chronic coronary syndrome: European Society of Cardiology criteria vs. CHADS-P2A2RC score. <i>European Heart Journal</i> , 2022, 43, 996-1004.	2.2	8
62	Accidentally crushed stent during complex bifurcation treatment. A potential cause of very late stent thrombosis. <i>International Journal of Cardiology</i> , 2015, 197, 113-115.	1.7	7
63	A Novel Model for Prediction of Thromboembolic and Cardiovascular Events in Patients Without Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2020, 131, 40-48.	1.6	7
64	The ABO Locus is Associated with Increased Fibrin Network Formation in Patients with Stable Coronary Artery Disease. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1248-1256.	3.4	7
65	Association of whole blood microRNA expression with platelet function and turnover in patients with coronary artery disease. <i>Thrombosis Research</i> , 2022, 211, 98-105.	1.7	7
66	Staged re-evaluation of non-culprit lesions in ST segment elevation myocardial infarction: a retrospective study. <i>Open Heart</i> , 2016, 3, e000427.	2.3	6
67	Micro- and macrovascular cardiac allograft vasculopathy in relation to 91 cardiovascular biomarkers in heart transplant recipients – An exploratory study. <i>Clinical Transplantation</i> , 2021, 35, e14133.	1.6	6
68	Effectiveness and Safety of Ticagrelor Implementation in Patients with Acute Coronary Syndrome undergoing Percutaneous Coronary Intervention: A Cohort Study in Western Denmark. <i>Lancet Regional Health - Europe, The</i> , 2022, 14, 100301.	5.6	6
69	Platelet count, platelet turnover and fibrin clot structure in patients with coronary artery disease. <i>Thrombosis Research</i> , 2014, 133, 1161-1163.	1.7	5
70	Gastroscopy-related adverse cardiac events and bleeding complications among patients treated with coronary stents and dual antiplatelet therapy. <i>Endoscopy International Open</i> , 2016, 04, E527-E533.	1.8	5
71	Ten-Year Outcomes of Sirolimus-Eluting Versus Zotarolimus-Eluting Coronary Stents in Patients With Versus Without Diabetes Mellitus (SORT OUT III). <i>American Journal of Cardiology</i> , 2020, 125, 349-353.	1.6	5
72	Insulin-treated versus noninsulin-treated diabetes and risk of ischemic stroke in patients with atrial fibrillation. <i>Vascular Pharmacology</i> , 2021, 136, 106809.	2.1	5

#	ARTICLE	IF	CITATIONS
73	Effect of remote ischaemic conditioning on platelet aggregation and platelet turnover. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 46, 528-533.	2.1	4
74	Agreement between nonculprit stenosis follow-up iFR and FFR after STEMI (iSTEMI substudy). <i>BMC Research Notes</i> , 2020, 13, 410.	1.4	4
75	Lower Antiplatelet Effect of Aspirin in Essential Thrombocythemia than in Coronary Artery Disease. <i>TH Open</i> , 2021, 05, e230-e238.	1.4	4
76	Reduced Effect of Aspirin and Clopidogrel Following Hybrid Coronary Revascularization. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2015, 21, 603-611.	1.7	3
77	Coronary stent implantation and adverse cardiac events after surgery. <i>European Journal of Clinical Investigation</i> , 2018, 48, e13030.	3.4	3
78	Cytoreductive treatment and association with platelet function and maturity in patients with essential thrombocythaemia. <i>British Journal of Haematology</i> , 2022, 198, 693-702.	2.5	3
79	Intracoronary vs intravenous abciximab in interventional cardiology: A reopened question?. <i>Vascular Pharmacology</i> , 2015, 73, 8-10.	2.1	2
80	Benefits and Harm of Treatment with P2Y12 Inhibitors beyond 12 Months in Patients with Coronary Artery Disease. <i>Seminars in Thrombosis and Hemostasis</i> , 2020, 46, 446-456.	2.7	2
81	Risk of Myocardial Infarction and Death After Noncardiac Surgery Performed Within the First Year After Coronary Drug-Eluting Stent Implantation for Acute Coronary Syndrome or Stable Angina Pectoris. <i>American Journal of Cardiology</i> , 2021, 160, 14-20.	1.6	2
82	Flow Cytometric Assessment of Changes in Platelet Reactivity after Acute Coronary Syndrome: A Systematic Review. <i>Seminars in Thrombosis and Hemostasis</i> , 2022, , .	2.7	2
83	Thrombopoietin and platelet aggregation in patients with stable coronary artery disease. <i>Platelets</i> , 2017, 28, 822-824.	2.3	1
84	The year in cardiology 2017: coronary interventions. <i>European Heart Journal</i> , 2018, 39, 914-924.	2.2	1
85	Instantaneous wave-free ratio cutoff values for nonculprit stenosis classification in patients with ST-segment elevation myocardial infarction (an iSTEMI substudy). <i>Coronary Artery Disease</i> , 2020, 31, 411-416.	0.7	1
86	Statistical and machine learning methods for analysis of multiplex protein data from a novel proximity extension assay in patients with ST-elevation myocardial infarction. <i>Scientific Reports</i> , 2021, 11, 13787.	3.3	1
87	The ACVC transatlantic collaboration: an initiative for exchange of knowledge and science. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 234-235.	1.0	0
88	Increased Inflammatory Markers in Patients with Reduced Antiplatelet Effect of Aspirin.. <i>Blood</i> , 2012, 120, 2252-2252.	1.4	0
89	Cardiovascular risks associated with smoking in patients without obstructive coronary artery disease. <i>European Journal of Preventive Cardiology</i> , 2022, 29, e14-e17.	1.8	0
90	CHA 2 DS 2 -CVASc impact on risk following percutaneous coronary intervention in atrial fibrillation. <i>European Journal of Clinical Investigation</i> , 2021, , e13717.	3.4	0

#	ARTICLE	IF	CITATIONS
91	Impact of diabetes on 1-year clinical outcome in patients undergoing revascularization with the BioFreedom stents or the Orsiro stents from the SORT OUT IX trial. Catheterization and Cardiovascular Interventions, 2022, , .	1.7	0